Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEADPACE: Liraglutide in T2DM with PAD
NCT04146155Phase 4Unknown
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- May 2020
- Primary completion
- Dec 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 4 trial of liraglutide in Peripheral Arterial Disease (PAD), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Status: unknown.
02
Drugs
03
Conditions
Peripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT04146155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04146155.